CHD

Business Context and Reporting Period

Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 27, 2009
Business Overview: The Company manufactures and markets household and personal care products (Consumer Domestic), personal care products (Consumer International), and specialty chemical products (Specialty Products Division). Key brands include ARM & HAMMER, OXICLEAN, and Orajel (acquired July 2008).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 5.1% ($28.0 million) year-over-year. Growth was driven by the Orajel acquisition (4.5% contribution), higher unit volumes, and price increases, partially offset by a 4.1% negative impact from foreign exchange rates and prior-year divestitures.
• Margin Expansion: Gross margin improved by 240 basis points to 42.9%, aided by lower commodity costs, the Orajel acquisition mix, and cost reduction programs. This was partially offset by a $5.2 million charge related to the planned closure of the North Brunswick, NJ facility.
• Expense Trends: Marketing expenses rose 24.1% ($12.9 million) to support new acquisitions and existing brands (ARM & HAMMER, OXICLEAN). SG&A remained relatively flat ($0.5 million increase) despite higher operating costs, as 2008 included a $3.0 million gain on asset sale and $5.6 million in impairment charges.
• Segment Performance:
  • Consumer Domestic: Sales up 14.5% and income up $12.1 million, driven by volume and the Orajel acquisition.
  • Consumer International: Sales down 17.0% due to a 20% foreign exchange headwind and the divestiture of a Spanish subsidiary, though income increased $3.5 million due to higher prices and the absence of 2008 impairment charges.
  • Specialty Products: Sales down 14.8% due to foreign exchange and the prior-year sale of Brotherton; income decreased $3.8 million.

Outlook, Risks, and Unusual Items

• Capital Expenditures: The Company is constructing a new laundry detergent plant in York County, PA, with a total estimated cost of $151.0 million. Approximately $14.7 million was spent in Q1 2009, with an additional $85.0 million expected in the remainder of 2009.
• Facility Closure: The North Brunswick, NJ facility is scheduled to close in 2009. Total expected costs include $4.2 million in severance, $6.6 million in exit/disposal costs, and $24.6 million in accelerated depreciation. A $4.5 million depreciation charge was recorded in Q1 2009.
• Liquidity and Debt: Net debt decreased to $591.0 million. The Company maintains a leverage ratio of 1.9x (limit 3.5x) and an interest coverage ratio of 10.8x (minimum 3.0x). Management believes cash flow and borrowing capacity are sufficient to meet obligations.
• Legal Proceedings: The Company won a patent infringement suit against Abbott Laboratories regarding pregnancy test kits, with damages doubled to $29.2 million by the District Court. Abbott has appealed, and the case is pending post-trial motions.
• Regulatory Risks: Ongoing FDA scrutiny regarding the spermicide nonoxynol-9 (N-9) in condoms could lead to labeling restrictions or sales declines.

Investor Verification Checklist

• Orajel Integration: Verify the realization of projected synergies and margin improvements from the Del Pharmaceuticals (Orajel) acquisition.
• York County Plant: Monitor capital expenditure burn rate and the timeline for the new facility's operational launch (expected end of 2009).
• North Brunswick Closure: Track the execution of the shutdown plan and the recognition of remaining non-cash depreciation and cash exit costs.
• Foreign Exchange Exposure: Assess the impact of currency fluctuations on the Consumer International segment, which saw a 20% negative FX impact in Q1.
• Abbott Litigation: Follow the status of the appeal regarding the $29.2 million patent infringement award.